Annual FCF
$361.60 M
+$38.70 M+11.99%
31 December 2023
Summary:
Neurocrine Biosciences annual free cash flow is currently $361.60 million, with the most recent change of +$38.70 million (+11.99%) on 31 December 2023. During the last 3 years, it has risen by +$128.50 million (+55.13%). NBIX annual FCF is now at all-time high.NBIX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$149.90 M
+$96.90 M+182.83%
30 September 2024
Summary:
Neurocrine Biosciences quarterly free cash flow is currently $149.90 million, with the most recent change of +$96.90 million (+182.83%) on 30 September 2024. Over the past year, it has increased by +$31.80 million (+26.93%). NBIX quarterly FCF is now -26.66% below its all-time high of $204.40 million, reached on 30 September 2023.NBIX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$440.10 M
-$54.50 M-11.02%
30 September 2024
Summary:
Neurocrine Biosciences TTM free cash flow is currently $440.10 million, with the most recent change of -$54.50 million (-11.02%) on 30 September 2024. Over the past year, it has increased by +$78.50 million (+21.71%). NBIX TTM FCF is now -28.37% below its all-time high of $614.40 million, reached on 31 March 2024.NBIX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +26.9% | +21.7% |
| 3 y3 years | +55.1% | +3289.4% | +88.8% |
| 5 y5 years | +173.3% | +58.3% | +232.7% |
NBIX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +66.2% | -26.7% | +212.1% | -28.4% | +330.6% |
| 5 y | 5 years | at high | +372.1% | -26.7% | +212.1% | -28.4% | +436.1% |
| alltime | all time | at high | +336.1% | -26.7% | +212.1% | -28.4% | +330.3% |
Neurocrine Biosciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $149.90 M(+182.8%) | $440.10 M(-11.0%) |
| June 2024 | - | $53.00 M(-55.5%) | $494.60 M(-19.5%) |
| Mar 2024 | - | $119.10 M(+0.8%) | $614.40 M(+69.9%) |
| Dec 2023 | $361.60 M(+12.0%) | $118.10 M(-42.2%) | $361.60 M(-6.0%) |
| Sept 2023 | - | $204.40 M(+18.3%) | $384.70 M(+37.0%) |
| June 2023 | - | $172.80 M(-229.2%) | $280.80 M(+18.3%) |
| Mar 2023 | - | -$133.70 M(-194.7%) | $237.30 M(-26.5%) |
| Dec 2022 | $322.90 M(+38.5%) | $141.20 M(+40.5%) | $322.90 M(+82.4%) |
| Sept 2022 | - | $100.50 M(-22.3%) | $177.00 M(+33.5%) |
| June 2022 | - | $129.30 M(-368.8%) | $132.60 M(+29.7%) |
| Mar 2022 | - | -$48.10 M(+923.4%) | $102.20 M(-56.2%) |
| Dec 2021 | $233.10 M(+7.1%) | -$4.70 M(-108.4%) | $233.10 M(-28.9%) |
| Sept 2021 | - | $56.10 M(-43.3%) | $327.80 M(+30.6%) |
| June 2021 | - | $98.90 M(+19.4%) | $250.90 M(-5.7%) |
| Mar 2021 | - | $82.80 M(-8.0%) | $266.20 M(+22.3%) |
| Dec 2020 | $217.60 M(+64.5%) | $90.00 M(-532.7%) | $217.60 M(-2.1%) |
| Sept 2020 | - | -$20.80 M(-118.2%) | $222.30 M(-34.1%) |
| June 2020 | - | $114.20 M(+233.9%) | $337.40 M(+19.3%) |
| Mar 2020 | - | $34.20 M(-63.9%) | $282.90 M(+113.8%) |
| Dec 2019 | $132.30 M(+72.7%) | $94.70 M(+0.4%) | $132.30 M(+61.2%) |
| Sept 2019 | - | $94.30 M(+58.0%) | $82.09 M(+85.1%) |
| June 2019 | - | $59.70 M(-151.3%) | $44.35 M(+9025.5%) |
| Mar 2019 | - | -$116.40 M(-361.6%) | $486.00 K(-99.4%) |
| Dec 2018 | $76.60 M(-175.6%) | $44.49 M(-21.3%) | $76.60 M(+9.0%) |
| Sept 2018 | - | $56.56 M(+257.1%) | $70.31 M(+4202.7%) |
| June 2018 | - | $15.84 M(-139.3%) | $1.63 M(-102.6%) |
| Mar 2018 | - | -$40.29 M(-205.5%) | -$62.84 M(-38.0%) |
| Dec 2017 | -$101.27 M(-8.2%) | $38.20 M(-415.3%) | -$101.27 M(-40.9%) |
| Sept 2017 | - | -$12.11 M(-75.1%) | -$171.44 M(-10.3%) |
| June 2017 | - | -$48.64 M(-38.2%) | -$191.11 M(+20.2%) |
| Mar 2017 | - | -$78.72 M(+146.2%) | -$159.06 M(+44.2%) |
| Dec 2016 | -$110.29 M(+176.2%) | -$31.97 M(+0.6%) | -$110.29 M(+16.9%) |
| Sept 2016 | - | -$31.79 M(+91.7%) | -$94.35 M(+15.8%) |
| June 2016 | - | -$16.58 M(-44.7%) | -$81.45 M(+58.4%) |
| Mar 2016 | - | -$29.95 M(+86.8%) | -$51.42 M(+28.8%) |
| Dec 2015 | -$39.93 M(-18.1%) | -$16.03 M(-15.1%) | -$39.93 M(+0.7%) |
| Sept 2015 | - | -$18.89 M(-240.4%) | -$39.65 M(+19.7%) |
| June 2015 | - | $13.45 M(-172.9%) | -$33.13 M(-42.1%) |
| Mar 2015 | - | -$18.46 M(+17.2%) | -$57.19 M(+17.3%) |
| Dec 2014 | -$48.75 M(+61.7%) | -$15.75 M(+27.3%) | -$48.75 M(+10.6%) |
| Sept 2014 | - | -$12.37 M(+16.5%) | -$44.07 M(+3.7%) |
| June 2014 | - | -$10.61 M(+5.9%) | -$42.52 M(+1.2%) |
| Mar 2014 | - | -$10.02 M(-9.5%) | -$42.03 M(+39.4%) |
| Dec 2013 | -$30.15 M(-16.9%) | -$11.07 M(+2.4%) | -$30.15 M(+7.6%) |
| Sept 2013 | - | -$10.81 M(+6.8%) | -$28.03 M(+8.5%) |
| June 2013 | - | -$10.12 M(-646.4%) | -$25.83 M(+13.3%) |
| Mar 2013 | - | $1.85 M(-120.7%) | -$22.80 M(-37.1%) |
| Dec 2012 | -$36.27 M(+2404.5%) | -$8.95 M(+4.0%) | -$36.27 M(+122.0%) |
| Sept 2012 | - | -$8.61 M(+21.3%) | -$16.33 M(+196.2%) |
| June 2012 | - | -$7.10 M(-38.9%) | -$5.51 M(+23.7%) |
| Mar 2012 | - | -$11.61 M(-205.7%) | -$4.46 M(+207.7%) |
| Dec 2011 | -$1.45 M(-102.9%) | $10.98 M(+396.8%) | -$1.45 M(-91.5%) |
| Sept 2011 | - | $2.21 M(-136.6%) | -$16.97 M(-6.4%) |
| June 2011 | - | -$6.04 M(-29.8%) | -$18.12 M(-134.1%) |
| Mar 2011 | - | -$8.60 M(+89.4%) | $53.22 M(+7.2%) |
| Dec 2010 | $49.63 M | -$4.54 M(-530.3%) | $49.63 M(+23.5%) |
| Sept 2010 | - | $1.05 M(-98.4%) | $40.20 M(+43.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $65.30 M(-635.8%) | $28.03 M(-155.1%) |
| Mar 2010 | - | -$12.19 M(-12.8%) | -$50.90 M(-4.2%) |
| Dec 2009 | -$53.13 M(-29.6%) | -$13.97 M(+25.8%) | -$53.13 M(-4.4%) |
| Sept 2009 | - | -$11.11 M(-18.5%) | -$55.59 M(-6.1%) |
| June 2009 | - | -$13.63 M(-5.4%) | -$59.20 M(-3.7%) |
| Mar 2009 | - | -$14.41 M(-12.3%) | -$61.45 M(-18.6%) |
| Dec 2008 | -$75.49 M(+25.9%) | -$16.43 M(+11.6%) | -$75.49 M(+19.0%) |
| Sept 2008 | - | -$14.73 M(-7.3%) | -$63.42 M(-10.1%) |
| June 2008 | - | -$15.88 M(-44.2%) | -$70.51 M(-4.1%) |
| Mar 2008 | - | -$28.45 M(+552.6%) | -$73.49 M(+22.6%) |
| Dec 2007 | -$59.96 M(-41.5%) | -$4.36 M(-80.0%) | -$59.96 M(-17.3%) |
| Sept 2007 | - | -$21.82 M(+15.7%) | -$72.48 M(-14.4%) |
| June 2007 | - | -$18.86 M(+26.4%) | -$84.69 M(-12.0%) |
| Mar 2007 | - | -$14.92 M(-11.6%) | -$96.29 M(-6.0%) |
| Dec 2006 | -$102.44 M(+169.4%) | -$16.89 M(-50.4%) | -$102.44 M(-8.1%) |
| Sept 2006 | - | -$34.02 M(+11.7%) | -$111.44 M(+232.8%) |
| June 2006 | - | -$30.46 M(+44.6%) | -$33.48 M(+5.9%) |
| Mar 2006 | - | -$21.07 M(-18.6%) | -$31.61 M(-16.9%) |
| Dec 2005 | -$38.03 M(-75.2%) | -$25.88 M(-158.9%) | -$38.03 M(-18.7%) |
| Sept 2005 | - | $43.93 M(-253.7%) | -$46.80 M(-55.3%) |
| June 2005 | - | -$28.59 M(+4.0%) | -$104.73 M(-20.7%) |
| Mar 2005 | - | -$27.49 M(-20.7%) | -$132.09 M(-13.7%) |
| Dec 2004 | -$153.13 M(+1050.4%) | -$34.65 M(+147.4%) | -$153.13 M(+11.3%) |
| Sept 2004 | - | -$14.01 M(-75.0%) | -$137.56 M(-2.3%) |
| June 2004 | - | -$55.94 M(+15.2%) | -$140.83 M(+14.1%) |
| Mar 2004 | - | -$48.54 M(+154.4%) | -$123.44 M(+827.3%) |
| Dec 2003 | -$13.31 M(-84.3%) | -$19.08 M(+10.4%) | -$13.31 M(-53.0%) |
| Sept 2003 | - | -$17.27 M(-55.2%) | -$28.33 M(+3.8%) |
| June 2003 | - | -$38.54 M(-162.6%) | -$27.28 M(+157.5%) |
| Mar 2003 | - | $61.58 M(-280.6%) | -$10.60 M(-87.5%) |
| Dec 2002 | -$84.67 M(+229.9%) | -$34.09 M(+110.1%) | -$84.67 M(+66.6%) |
| Sept 2002 | - | -$16.23 M(-25.7%) | -$50.83 M(+36.8%) |
| June 2002 | - | -$21.86 M(+75.1%) | -$37.15 M(+28.0%) |
| Mar 2002 | - | -$12.48 M(+4796.1%) | -$29.03 M(+13.1%) |
| Dec 2001 | -$25.66 M(+21.7%) | -$255.00 K(-90.0%) | -$25.66 M(-19.8%) |
| Sept 2001 | - | -$2.55 M(-81.4%) | -$31.98 M(+0.3%) |
| June 2001 | - | -$13.74 M(+50.8%) | -$31.88 M(+15.1%) |
| Mar 2001 | - | -$9.12 M(+38.7%) | -$27.69 M(+31.3%) |
| Dec 2000 | -$21.09 M(+70.0%) | -$6.57 M(+168.4%) | -$21.09 M(+68.5%) |
| Sept 2000 | - | -$2.45 M(-74.4%) | -$12.51 M(-15.2%) |
| June 2000 | - | -$9.55 M(+280.0%) | -$14.76 M(+43.1%) |
| Mar 2000 | - | -$2.51 M(-225.7%) | -$10.31 M(-16.8%) |
| Dec 1999 | -$12.40 M(-13.9%) | $2.00 M(-142.6%) | -$12.40 M(-29.9%) |
| Sept 1999 | - | -$4.70 M(-7.8%) | -$17.70 M(+21.2%) |
| June 1999 | - | -$5.10 M(+10.9%) | -$14.60 M(+13.2%) |
| Mar 1999 | - | -$4.60 M(+39.4%) | -$12.90 M(-10.4%) |
| Dec 1998 | -$14.40 M(-413.0%) | -$3.30 M(+106.3%) | -$14.40 M(+161.8%) |
| Sept 1998 | - | -$1.60 M(-52.9%) | -$5.50 M(-523.1%) |
| June 1998 | - | -$3.40 M(-44.3%) | $1.30 M(-138.2%) |
| Mar 1998 | - | -$6.10 M(-208.9%) | -$3.40 M(-173.9%) |
| Dec 1997 | $4.60 M(+4.5%) | $5.60 M(+7.7%) | $4.60 M(-45.9%) |
| Sept 1997 | - | $5.20 M(-164.2%) | $8.50 M(+431.3%) |
| June 1997 | - | -$8.10 M(-526.3%) | $1.60 M(-82.6%) |
| Mar 1997 | - | $1.90 M(-80.0%) | $9.20 M(+109.1%) |
| Dec 1996 | $4.40 M | $9.50 M(-658.8%) | $4.40 M(-186.3%) |
| Sept 1996 | - | -$1.70 M(+240.0%) | -$5.10 M(+50.0%) |
| June 1996 | - | -$500.00 K(-82.8%) | -$3.40 M(+17.2%) |
| Mar 1996 | - | -$2.90 M | -$2.90 M |
FAQ
- What is Neurocrine Biosciences annual free cash flow?
- What is the all time high annual FCF for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly free cash flow?
- What is the all time high quarterly FCF for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly FCF year-on-year change?
- What is Neurocrine Biosciences TTM free cash flow?
- What is the all time high TTM FCF for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM FCF year-on-year change?
What is Neurocrine Biosciences annual free cash flow?
The current annual FCF of NBIX is $361.60 M
What is the all time high annual FCF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual free cash flow is $361.60 M
What is Neurocrine Biosciences quarterly free cash flow?
The current quarterly FCF of NBIX is $149.90 M
What is the all time high quarterly FCF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly free cash flow is $204.40 M
What is Neurocrine Biosciences quarterly FCF year-on-year change?
Over the past year, NBIX quarterly free cash flow has changed by +$31.80 M (+26.93%)
What is Neurocrine Biosciences TTM free cash flow?
The current TTM FCF of NBIX is $440.10 M
What is the all time high TTM FCF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM free cash flow is $614.40 M
What is Neurocrine Biosciences TTM FCF year-on-year change?
Over the past year, NBIX TTM free cash flow has changed by +$78.50 M (+21.71%)